Sionna Therapeutics Inc (SION)

$5.87 -0.19 (-3.14%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	273.99M
Revenue (ttm)	0.00
Net Income (ttm)	-75.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	784,600
Avg Vol	2,175,560
Day's Range	N/A - N/A
Shares Out	45.21M
Stochastic %K	61%
Beta	1.33
Analysts	Sell
Price Target	$5.50

Company Profile

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 819 2020

Website: www.sionnatx.com

Address:

21 Hickory Drive, Suite 500, Waltham, United States